Inactive Instrument

Press Releases Onxeo OTC Markets

Equities

OXNXF

FR0010095596

Press Releases

Unlock all the news: Be the first to know and act before the market!

Valerio Therapeutics : Inside Information / Other news releases	06-05	PU
Valerio Therapeutics: Report on the Combined General Meeting of June 4, 2024	06-05	BU
Valerio Therapeutics : Reports Full Year 2023 Financial Results and Provides Clinical Development Updates	05-24	PU
Valerio Therapeutics Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial	05-22	BU
Valerio Therapeutics : Publication of the 2023 Annual Report	05-22	PU
Valerio Therapeutics : Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States	05-13	PU
Valerio Therapeutics : Onxeo Announces the Transfer of the Listing of its Shares to Euronext Growth Paris on December 15, 2020	05-13	PU
Valerio Therapeutics : Annual financial and audit reports / Terms of availability of the annual financial report	05-01	PU
Valerio Therapeutics Reports Full Year 2023 Financial Results and Provides Clinical Development Updates	04-30	BU
Valerio Therapeutics : Reports Full Year 2023 Financial Results and Provides Clinical Development Updates	04-30	PU
Valerio Therapeutics : Publication of the 2023 Annual Report	04-30	PU
Onxeo : changes its name and becomes Valerio Therapeutics following approval by the Annual General Meeting of June 6, 2023	06/06/23	PU
Onxeo: Publication of the 2022 Annual Financial Report	28/04/23	BU
Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates	24/04/23	BU
Onxeo will publish its full-year results on April 24, 2023	21/04/23	BU
Onxeo : Terms of availability of the preparatory documents for the GM	18/01/23	PU
Half-year liquidity contract statement for ONXEO	04/01/23	BU
Onxeo : Inside Information / News release on accounts, results	13/09/22	PU
Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities	13/09/22	BU
High-Grade Glioma Relapse in Children: Onxeo Announces the Enrollment of the First Patient in the Phase 1b/2 Clinical Study Conducted by the European ITCC Consortium and Sponsored by Institut Curie	01/09/22	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Onxeo OTC Markets

Equities

OXNXF

FR0010095596

Press Releases

Filters